glp-1 market news New news: a major ad-trust fight just hit the weight loss drug space. The Guardian reports Ozempic maker Novo Nordisk is suing a US rival over what it calls “materially GLP-1 Market Trends | Whitepaper

I lose all sense of time passing

Rho-family GTPases are central regulators of actin cytoskeletal rearrangement 28

RME relies on the inclusion of proteins into micellar inner cores, and the subsequent release in the aqueous phase

The states second-largest insurer, Point32Health (which includes Harvard Pilgrim Health Care and Tufts Health Plan) has said it has no plans to change its coverage of GLP-1s, although it, like Blue Cross, has racked up hundreds of millions of dollars in losses, much of it driven by soaring demand for obesity drugs

For anti-aging goals, this is when before/after comparisons show the most dramatic differences